Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women With Node-Positive Breast Cancer.
This is the first decision impact study to include exclusively women with ER-positive, HER2-negative, early-stage breast cancer with 1-3 positive lymph nodes, a population typically treated with adjuvant chemotherapy. This study provides evidence that, in these patients, the Oncotype Dx Recurrence Score assay influences systemic treatment decisions. Most of the changes in treatment recommendation resulted […]
